Arrowhead boasts a diversified RNAi pipeline targeting liver, lung, muscle, CNS, and obesity. Read why I recommend buying and ...

Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...

Looking for cheap 400-hp muscle? Here are 10 used V8 cars that mix serious power with surprising affordability on the used ...

Relmada Therapeutics (RLMD) is a clinical-stage pharma company with no commercialized products and a $141 million market cap.

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive ...

Research and development expenses for the third quarter of 2025 increased to $9.6 million from $8.1 million for the prior year period. The increase was primarily due to a $0.9 million increase in ...

Net income from continuing operations of $5.9 million in Q3 2025 Gross margin increased 20.0% sequentially to 49.4% Balance sheet at September 30, 2025, strongest in the Company’s history with $81.5 ...

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...